1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   Response - Informed Consent Form
   Response - Clinical Study Report
   Response (Others) -  NIL
   
3. Who will be able to view these files?
   Response (Others) -  NIL


4. For what types of analyses will this data be available?
   Response (Others) -  NIL


5. By what mechanism will data be made available?
   Response (Others) -  NIL


6. For how long will this data be available start date provided 10-04-2029 and end date provided 10-04-2034?
   Response (Others) -  NIL


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

Rationale The administration of Rabies Immunoglobulin RIG is a painful procedure. Local application of painrelieving medications has been used for many other procedures effectively. Assessing antibody titres helps to see whether a lignocaine medicated pad interferes with immune response. It also provides an opportunity to determine effective immune response and factors affecting it. Novelty No previous studies other than a small clinical trial by our team. Objectives To find the effect 2 percent Lignocaine Medicated Pad LMP on pain relief and antibody response during Rabies Immunoglobulin administration factors determining antibody response, frequency of adverse events following RIG administration and cost effectiveness of procedure. Methods A randomized triple blind controlled trial will be done in three sites in India in tertiary care settings. Patients with Category III animal bite wounds will be randomized to intervention and placebo arms based on a previously generated random number sequence. Sterile gauze pads soaked with 2% lignocaine and normal saline will be intervention and placebo, respectively. Pain relief and antibody response will be the primary outcomes measured. Pain relief will be assessed using a numeric rating scale NRS and sound, eye and motor pain SEM scale. Costeffectiveness will be assessed by calculating the incremental cost-effectiveness ratio ICER determining the willingness to pay WTP threshold by the contingent valuation method. If the ICER falls below this WTP threshold the intervention will be considered cost-effective. Expected Outcome A cost-effective procedure for pain relief during RIG administration, which can be included in the national policy and guidelines for rabies management.